Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).

[1]  Benjamin Movsas,et al.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.

[2]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[3]  N. O'Rourke,et al.  Concurrent chemoradiotherapy in non-small cell lung cancer. , 2010, The Cochrane database of systematic reviews.

[4]  Y. Nishiwaki,et al.  Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202 , 2008, Radiation oncology.

[5]  J. Jett,et al.  The value of combined‐modality therapy in elderly patients with stage III nonsmall cell lung cancer , 2007, Cancer.

[6]  H. Groen,et al.  Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  C. Gridelli,et al.  Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. , 2005, Chest.

[8]  N. Saijo,et al.  Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). , 2005, Japanese journal of clinical oncology.

[9]  H. Groen,et al.  Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  A. Piga,et al.  Elderly Patients with Advanced Non-Small Cell Lung Cancer , 2003, Oncology.

[11]  J. Jett,et al.  The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Balducci,et al.  A case for geriatric oncology. , 2002, The Lancet. Oncology.

[13]  David Cella,et al.  Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.

[14]  W. Curran,et al.  Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? a secondary analysis of RTOG 94-10 , 2001 .

[15]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[16]  N. Masuda,et al.  Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. , 2000, Japanese journal of clinical oncology.

[17]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[18]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Joseph,et al.  A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  R. Tokars,et al.  Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[22]  C. Gridelli,et al.  Lung cancer in the elderly. , 1994, European journal of cancer.

[23]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.

[24]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.

[25]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.

[26]  E. Douple,et al.  Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells. , 1986, International journal of radiation oncology, biology, physics.

[27]  D. Lydall,et al.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.

[28]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[29]  D. Schoenfeld,et al.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. , 1982, Biometrics.

[30]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[31]  P. Lambin,et al.  Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Y. Ung,et al.  Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. , 2004, International journal of radiation oncology, biology, physics.

[33]  I. Smith,et al.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II , 2004, Cancer Chemotherapy and Pharmacology.

[34]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[35]  W. Sause,et al.  The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. , 1999, International journal of radiation oncology, biology, physics.

[36]  J. Herndon,et al.  Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  下山正徳.  National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 2.0, Jan. 30, 1998)-日本語訳JCOG版- , 1999 .

[38]  M. Fukuoka,et al.  Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer , 1997, Cancer Chemotherapy and Pharmacology.

[39]  J. Yarnold,et al.  Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. , 1985, Cancer treatment reports.